Reducing Duration and Incidence of Select Symptomatic Adverse Events with Evinova Remote Patient Monitoring
Clinical trials don’t only occur at the study site. For many patients, sometimes the most challenging moments happen at home — where health status worsens due to emerging toxicities or disease progression. The only support available is a printed instruction sheet and recall of the nurse instructions after signing consent to be part of the clinical trial.
That gap has consequences. Symptoms emerge and worsen without clinical awareness. Medication adherence slips. By the time a patient returns for their next scheduled visit, some post-infusion details have faded, early warning signals have passed, and opportunities for timely intervention have been missed.
This is the problem that Evinova Remote Patient Monitoring (RPM) is designed to solve. By enabling daily, at-home capture of patient-reported symptoms, medication intake, and physiological data through connected devices, RPM gives clinical teams a continuous window into patient health status between site visits. Automated alerts notify teams when readings fall outside predefined ranges — allowing them to identify high-risk patients earlier and act before adverse events escalate.
For patients, complex protocols are broken down into simple daily tasks, reducing burden and supporting more consistent engagement with site teams. For sponsors and clinical teams, automated adherence logs and early signals mean treatment decisions can be grounded in more timely insights. Together, these capabilities position RPM as a meaningful step forward in how toxicity is managed in clinical trials.
Evidence in Action: Proactive Monitoring Elevates Patient Care and Improves Outcomes in GI Trials
Gastrointestinal adverse events are among the most common factors contributing to dose reductions or treatment discontinuation in oncology trials. These events are also frequently underreported between scheduled visits, as patients may tolerate or manage symptoms independently and delay reporting them until the next clinical assessment, by which time the symptoms may have worsened.
Average GI Adverse Event Duration in Days
This is where continuous, patient-reported monitoring can help identify symptom patterns earlier and support more timely intervention. Data from Evinova’s Digestive RPM module demonstrate a meaningful reduction in the number of days patients experienced GI adverse events across every severity grade, suggesting the potential to improve a patient’s experience while on treatment.
Additionally, RPM users had a lower overall incidence of GI adverse events. The data suggest that more continuous monitoring may help identify early signs of toxicity and enable intervention before symptoms progress or become more burdensome for patients.
Patients using RPM had fewer GI Adverse Events
Selected GI AEs include Constipation, Nausea, Decreased appetite, Diarrhea, Vomiting, Enteritis, Colitis, Gastritis (all grade)
Data from ongoing trials confirm consistently high patient compliance and strong concordance between investigator- and patient-reported adverse events, validating RPM as a reliable input for safety monitoring.
Why This Matters for Patients, Sites and Sponsors
For patients, reducing the duration and incidence of GI adverse events can make treatment less burdensome and help them remain on therapy with fewer interruptions, especially when supported by the self-management tips and behavior modification nudges in Evinova’s RPM modules. Earlier visibility into symptoms also creates more opportunities for clinical teams to respond before adverse events worsen or become dose-limiting.
For sites, proactive monitoring can support more informed patient management between scheduled visits. By giving clinical teams a more continuous view of symptom progression, RPM may help prioritize follow-up, guide timely interventions and reduce the burden of managing toxicity only once it has escalated.
For sponsors, these patient and site benefits can translate into stronger trial execution. When patients are better supported and adverse events are managed earlier, studies may see fewer dose modifications, discontinuations and protocol deviations, helping preserve data quality and strengthen the evidence generated.
“Remote patient monitoring gives clinical teams a more continuous view of how patients are experiencing treatment between visits. By identifying early signals of toxicity sooner, we can support more timely intervention, reduce avoidable burden for patients and generate stronger evidence for sponsors.”
Move Beyond Reactive Toxicity Monitoring
